Navigation Links
Medicago initiates work on Swine Flu strain
Date:4/28/2009

QUEBEC CITY, April 28 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has received a genetic sequence of the new strain of influenza A (H1N1) that has recently been identified in USA and Mexico, and has commenced laboratory work with its VLP vaccine technology to produce material for testing. According to the World Health Organization ("WHO"), a genetic analysis shows this new flu strain is a never-before-seen mixture of swine, human and avian viruses and has the potential of becoming a pandemic. The Company has already expressed VLPs of the following pandemic strains in plants: Singapore (H2N2), Anhui (H5N1), Vietnam (H5N1), Hong Kong (H6N1 and H9N2), Equine/Prague (H7N7), and of the seasonal strains New Caledonia (H1N1), Solomon Island (H1N1) and Brisbane (H1N1). Medicago is keeping health authorities informed on its work.

Medicago's H5N1 pandemic VLP vaccine has shown to be immunogenic at doses as low as 5 micrograms in preclinical studies and provided 100% cross-protection to different strains of the H5N1 virus in an animal model. The Company's proprietary plant-based manufacturing technology could deliver a vaccine, just one month after the identification of the genetic sequence from an emerging pandemic strain. This vaccine would then be tested in animals and humans and reviewed by Health Canada before it is produced on a commercial scale. Medicago recently had a pre-Clinical Trial Application ("CTA") meeting with Health Canada's Biologics and Genetic Therapies Directorate ("BGTD"). Based on the outcome of the meeting, the Company is finalising pre-clinical studies and preparing to move ahead with the submission of a CTA for its lead H5N1 pandemic VLP vaccine and with final approval will initiate a Phase I clinical trial in the third quarter of 2009.'/>"/>

SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
3. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
4. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
5. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
6. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
7. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
8. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
9. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
10. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
11. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., , NOVATO, Calif., Nov. 30 /PRNewswire-Firs...MRN ) announced today that the Food and Drug Admin...n for 3,4-diaminopyridine (3,4-DAP), amifampridine...t Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has p...E.U. Also, in October 2009, the Committee for Med...
(Date:11/30/2009)..., , BOSTON and COPENHAGEN, Nov. 30 /PRNew...) announced today that the Harvard Medical School ... recognized as a MicroRNA Screening Center of Exce...Medical School, and associated hospitals and insti...lecule and RNAi libraries. ,, MicroRNAs are a n...
(Date:11/30/2009)..., , AMSTERDAM,...he world,s,leading publisher of scientific, medica...nced a major re-launch of Embase, its comprehensiv...indexed records from more than 7,000,active, peer ...ed a key role in the advancement of new biomedical...
(Date:11/27/2009)..., , DURHAM, N.C., Nov. 27 /PRNewswire...k, will initiate water-soluble carbon nanotube-bas.... The water-soluble carbon nanotubes, which have f...ugation with cancer drugs, was developed in partne...he conjugated carbon nanotubes serves as a drug de...
Breaking Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2
...assay for inhibition of poly(ADP-ribose) polymeras...es the inhibition of PARP-activated incorporation ...NAD). The incorporation is detected using Europium...way to screen test compounds for PARP activity in ...reening. , Poly(ADP-ribose) polymerase (PA...
...ts (QDs) have potential applications, ...emory devices, and sources of laser ..., herein to possess a nonlinear change ...correlated to size and composition, as monitored b...pectrofluorometer. The QDs, emission wavelength,...
... Many companies claim high sensitivity for their ...rument vendors often cite excitation of de-ionized...at 397 nm (an energy loss of 3380 cm 1 ). This Ram...nal is red-shifted and weak, thus mimicking weak f...making sample-to-sample reproducibility straightfo...
Other Biology Technology:A DELFIA Assay for Inhibition of PARP 2A DELFIA Assay for Inhibition of PARP 3Photoluminescence Spectroscopy of Quantum Dots, monitored by the Spex FluoroMax 2Photoluminescence Spectroscopy of Quantum Dots, monitored by the Spex FluoroMax 3Photoluminescence Spectroscopy of Quantum Dots, monitored by the Spex FluoroMax 4Wideband sensitivity of the FluoroLog-3 2
(Date:12/1/2009)...s an ,abominable mystery, and it is a question whi... when did flowering plants evolve and how did they...dy in Ecology Letters reveals the evolutionary t... a major competitive advantage over rival species,..., The study, by Dr Tim Brodribb and Dr Taylor Fi...
(Date:11/30/2009)... review of the state of Antarctica,s climate and i...blished this week (Tuesday 1 December) by the Scie...e review - Antarctic Climate Change and the Enviro...ontinent, identifies areas for future scientific r...olicy makers have about Antarctic melting, sea-lev...
(Date:11/30/2009)...of Pittsburgh team overcame a major hurdle plaguin...hat could lead to more efficient catalysts used to...c. The researchers reported Nov. 29 in Nature Mat...e stability in metallic nanoparticles, the vaunted...lity to extreme heat. , Gtz Veser, an associate ...
Breaking Biology News(10 mins):How did flowering plants evolve to dominate Earth? 2First comprehensive review of the state of Antarctica's climate 2First metallic nanoparticles resistant to extreme heat 2Sherman Oaks Hospital Opens New Cardiac Catheterization Laboratory and Reopens Behavioral Health Facility for Seniors 55349 1Sherman Oaks Hospital Opens New Cardiac Catheterization Laboratory and Reopens Behavioral Health Facility for Seniors 55349 2Sherman Oaks Hospital Opens New Cardiac Catheterization Laboratory and Reopens Behavioral Health Facility for Seniors 55349 3Iowa Drug Card a Huge Success With Iowans 55345 1Iowa Drug Card a Huge Success With Iowans 55345 2Burner Balm Responds to Barrage of UK Protests Over New Lip Balm 55340 1Burner Balm Responds to Barrage of UK Protests Over New Lip Balm 55340 2
... MADISON Pfizer Inc., a major biopharmaceutical ...ion (WARF), the private, nonprofit patenting and l...sin-Madison, announced May 5 that they have signed...ents for the development of new drug therapies. , ...rk with hES cells for drug research and discovery....
... , An effort is under way at the University of Hou...obile industry to develop new tools that will help...rapy for patients with head and neck cancer. , Dr... Free Form Fabrication Laboratory at UH and a form.... Lei Dong, associate professor and deputy researc...
... The National Center for Research Resources (NCRR...unced today it will provide up to an estimated $12...tional Development Award (IDeA) Networks of Biomed...gible states. By promoting the development, coordi...tise, these awards expand research opportunities a...
Other Biology News:WARF signs license agreement with Pfizer for human embryonic stem cells 2From cars to cancer: UH professor employs auto industry tools for tumor therapy 2From cars to cancer: UH professor employs auto industry tools for tumor therapy 3From cars to cancer: UH professor employs auto industry tools for tumor therapy 4NIH grants $122 million in Institutional Development Awards 2NIH grants $122 million in Institutional Development Awards 3
Tricyclic Antidepressents ELISA Kit, Single from Bio-Quant Inc.
VZV IgM ELISA Kit, Single from Bio-Quant Inc.
Scion Image for Windows from Scion Corporation
...mbion's custom siRNA service provides the premium ...search. Custom siRNAs can be readily ordered onlin...ce, or by providing the sense and antisense siRNA ...ated and Silencer Pre-designed siRNAs, which are a...
Biology Products: